Givaudan SA GIVN
SIX SwissSpecialty chemicalsFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| CHF B | Dec 31 | Jun 30 |
|---|---|---|
| Cash | 0.7 | 0.3 |
| Securities | 0.0 | 0.0 |
| Debt | 4.0 | 4.5 |
| Net cash | -3.3 | -4.2 |
| Equity | 4.5 | 4.4 |
- Debt / EBITDA
- 2.78×
- Debt / equity
- 1.03×
- Leases (6/30/26)
- CHF 389M
- Diluted shares
- 9M
- Book value / share
- CHF 473.48
- Price / book
- 8.5×
- Net cash / share
- −CHF 453.37
- Market cap
- CHF 37.5B
- Enterprise value
- CHF 41.7B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 halves |
|---|---|---|---|
| Revenue growth | -1.7% | -5.1 pts | |
| Operating margin | 16.7% | -3.0 pts | |
| FCF margin | -0.6% | -2.5 pts | |
| Capex / revenue | 5.5% | +0.9 pts | |
| Research and product development spending | CHF 286M | +4% | |
| Net working capital as a share of sales | 30.8% | +3.7 pts | |
| Taste & Wellbeing like-for-like sales growth | +2% | – | |
| Fragrance & Beauty like-for-like sales growth | +9% | – | |
| Fine Fragrance like-for-like sales growth | +15% | – |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About GIVN
Givaudan supplies customer-specific flavours, fragrances and related ingredients to food, beauty and consumer-product brands. In 2025, Fragrance & Beauty supplied 51.3% of sales and Taste & Wellbeing 48.7%.
- Design In Qualification
Customer wins are typically brief-driven and co-created; qualification and reformulation make supplier switching costly for branded food & beverage manufacturers.
- Scope Economies
Breadth across flavours, taste solutions, and adjacent functional/natural ingredients enables integrated solutions and cross-selling to the same customer R&D teams.
- Capex Knowhow Scale
Scaled innovation platform (creation and application centres, R&D spend, patents) supports faster product cycles and customer-specific solutions across categories.
- Operational Excellence
Givaudan manages a complex global sourcing and customer-application network.
- Sep 29, 2026
The CMA kept its fragrance investigation open with a December update planned; Givaudan continues to face legal uncertainty without an infringement finding.
- Sep 21, 2026
Givaudan gained dual independent certification for its product carbon-footprint programme covering more than 90,000 products; standardised data helps customers meet procurement and reporting needs.
- Sep 16, 2026
A US court gave final approval to IFF’s end-user fragrance settlement. It leaves the claims against Givaudan and other defendants in place, so a competitor’s settlement does not end Givaudan’s civil exposure.
- Jul 23, 2026
Givaudan reported CHF 83m of H1 legal settlements and provisions, reducing profit and showing that customer relationships do not protect against regulatory and product-liability exposure.
- Jun 30, 2026 · Half year · Legal charge −CHF 83M
Fragrance competition settlement and a provision for an adverse Missouri judgment on alleged lung injury from diacetyl and 2,3 pentanedione. The filing reports one combined amount, so the two cases cannot be split.
Ownership
Go deeper on GIVN
- Compare stock research toolsFundamentals, valuation and screening platforms for GIVN.19 tools
- See GIVN's price chartNo price chart here yet. See price history and indicators.17 tools
- Read GIVN's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (CHF) | |||||||||||||
| Revenue | 502.09 | 543.94 | 594.84 | 667.93 | 680.38 | 719.42 | 769.14 | 747.06 | 799.87 | 805.51 | 796.71 | +5.4%/yr | |
| Cash flow | 86.68 | 92.72 | 98.58 | 122.32 | 127.96 | 138.63 | 102.45 | 148.33 | 175.36 | 163.00 | 155.75 | +7.3%/yr | |
| Earnings | 69.34 | 77.54 | 71.36 | 75.59 | 79.96 | 88.37 | 92.51 | 96.47 | 117.63 | 115.46 | 102.61 | +5.8%/yr | |
| Free cash flow | 67.73 | 66.34 | 66.94 | 87.87 | 103.53 | 111.08 | 69.60 | 118.62 | 143.74 | 130.12 | 119.39 | +7.5%/yr | |
| Capex | 18.95 | 26.38 | 31.64 | 34.46 | 24.43 | 27.55 | 32.85 | 29.71 | 31.62 | 32.88 | 36.36 | +6.3%/yr | |
| Dividends | 53.30 | 55.46 | 57.47 | 59.44 | 61.45 | 63.40 | 65.60 | 66.66 | 67.66 | 69.53 | 71.42 | +3.0%/yr | |
| Book value | 354.57 | 381.01 | 399.29 | 391.95 | 375.60 | 422.89 | 457.36 | 431.38 | 494.03 | 489.11 | 473.48 | +3.6%/yr | |
| Diluted shares (M) | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | -0.0%/yr | |
| Totals (CHF B) | |||||||||||||
| Revenue | 4.7 | 5.1 | 5.5 | 6.2 | 6.3 | 6.7 | 7.1 | 6.9 | 7.4 | 7.5 | 7.4 | +5.4%/yr | |
| Operating income | 0.9 | 0.9 | 0.9 | 0.9 | 1.0 | 1.1 | 1.1 | 1.1 | 1.4 | 1.4 | 1.3 | +5.2%/yr | |
| Net income | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.9 | 0.9 | 1.1 | 1.1 | 1.0 | +5.8%/yr | |
| Free cash flow | 0.6 | 0.6 | 0.6 | 0.8 | 1.0 | 1.0 | 0.6 | 1.1 | 1.3 | 1.2 | 1.1 | +7.5%/yr | |
| Buybacks | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | – | -6.8%/yr | |
| Dividends | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 | +3.0%/yr | |
| Net cash | -0.9 | -1.1 | -2.8 | -3.2 | -3.6 | -4.0 | -4.1 | -3.9 | -3.6 | -3.3 | -4.2 | −CHF 2.3B | |
| Margins & returns (%) | |||||||||||||
| Gross margin | 45.6 | 44.5 | 42.1 | 40.8 | 42.1 | 42.7 | 38.8 | 41.2 | 44.1 | 43.5 | 43.7 | -2.1 pts | |
| Operating margin | 18.8 | 17.2 | 16.0 | 14.8 | 15.8 | 16.3 | 15.6 | 16.1 | 18.8 | 18.5 | 16.9 | -0.3 pts | |
| Net margin | 13.8 | 14.3 | 12.0 | 11.3 | 11.8 | 12.3 | 12.0 | 12.9 | 14.7 | 14.3 | 12.9 | +0.5 pts | |
| FCF margin | 13.5 | 12.2 | 11.3 | 13.2 | 15.2 | 15.4 | 9.0 | 15.9 | 18.0 | 16.2 | 15.0 | +2.7 pts | |
| ROIC | 17.5 | 16.0 | 11.4 | 11.3 | 11.9 | 11.6 | 11.3 | 12.0 | 14.5 | 15.0 | 12.3 | -2.6 pts | |
| Return on equity | 19.6 | 20.4 | 17.9 | 19.3 | 21.3 | 20.9 | 20.2 | 22.4 | 23.8 | 23.6 | 21.7 | +4.0 pts | |
| R&D % of revenue | 8.6 | 8.4 | 8.6 | 8.5 | 8.5 | 8.4 | 7.3 | 7.5 | 7.6 | 7.4 | 7.6 | -1.2 pts | |
| Stock pay % of revenue | 0.7 | 0.7 | 0.7 | 0.7 | 0.9 | 1.0 | 0.1 | 0.4 | 0.8 | 0.7 | 0.9 | -0.0 pts | |
| Capex % of revenue | 3.8 | 4.9 | 5.3 | 5.2 | 3.6 | 3.8 | 4.3 | 4.0 | 4.0 | 4.1 | 4.6 | +0.3 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- durable
- Trajectory
- stable
- Pricing power
- strong
- Taste & Wellbeing48.7%4 claims
- Fragrance & Beauty51.3%3 claims
Moat claims
- Applies to
- Taste & Wellbeing
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 6, 2026
Customer wins are typically brief-driven and co-created; qualification and reformulation make supplier switching costly for branded food & beverage manufacturers.
Taste & Wellbeing grew 0.5% like-for-like in H1 2026; price increases and customer-specific recipes still support retention, but weak demand limits growth.
- Taste & Wellbeing like-for-like sales growth+2%
- Customer consolidation increases buyer power
- Commoditisation of standard flavours
- Large customers dual-source or insource flavour development
- SourceGivaudan Investor Presentation (July 2023)Jul 1, 2023
- NewsGivaudan 2026 half-year resultsJul 23, 2026
- Applies to
- Taste & Wellbeing
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 6, 2026
Breadth across flavours, taste solutions, and adjacent functional/natural ingredients enables integrated solutions and cross-selling to the same customer R&D teams.
The wider ingredient palette still supports integrated customer projects, but 0.5% H1 2026 like-for-like growth provides no evidence that cross-selling is accelerating.
- Taste & Wellbeing like-for-like sales growth+2%
- Customers prefer best-of-breed specialists over integrated bundles
- Portfolio breadth increases complexity and integration risk (acquisitions)
- Source2025 Investor Presentation (updated October 2025)Oct 1, 2025
- ResultsTranscript - 2024 Full Year ResultsJan 24, 2025
- Applies to
- Taste & Wellbeing
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 6, 2026
Scaled innovation platform (creation and application centres, R&D spend, patents) supports faster product cycles and customer-specific solutions across categories.
Group research spending reached CHF 551m in 2025 and CHF 286m in H1 2026; sustained investment protects know-how, but Taste & Wellbeing growth remains weak.
- Taste & Wellbeing like-for-like sales growth+2%
- Research and product development spendingCHF 286M+4%
- Active patents≥5,000
- Creation and application centres62
- Key talent attrition (flavourists, application scientists)
- AI-enabled formulation tools becoming widely available
- SourceGivaudan investor presentation updated October 2025Oct 1, 2025
- SourceGivaudan Investor Presentation (July 2023)Jul 1, 2023
- Applies to
- Taste & Wellbeing
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Oct 6, 2026
Givaudan manages a complex global sourcing and customer-application network. Carbon-footprint certification helps customer procurement, but the fatal Louisville reactor explosion exposed serious weaknesses in process safety. The network offers a modest service advantage; operating reliability needs stronger evidence.
The May 2026 CSB report found critical safety failures after an explosion that killed two workers and permanently closed the Louisville plant; this weakens the case for superior operating execution.
- Net working capital as a share of sales30.8%+3.7 pts
- Products with certified carbon-footprint data≥90,000
- Inadequate process-safety safeguards can cause fatalities, permanent plant losses and uninsured claims
- Climate and crop volatility in naturals
- Geopolitical disruption, tariffs, and shipping constraints
- Supplier concentration in certain naturals
- SourceUS Chemical Safety Board final Louisville explosion investigationMay 27, 2026
- NewsGivaudan product carbon footprint programme certifiedSep 21, 2026
- SourceGivaudan Investor Presentation (July 2023)Jul 1, 2023
- ResultsTranscript - 2024 Full Year ResultsJan 24, 2025
- Applies to
- Fragrance & Beauty
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 6, 2026
Givaudan develops fragrance formulas to customer specifications. Changing suppliers usually requires reformulation, stability and consumer testing, and new regulatory work. Those costs encourage repeat orders and support prices or product mix.
Fragrance & Beauty grew 6.5% like-for-like in H1 2026, with Consumer Products up 9.2%; demand supports embedded formulas despite stronger peer performance.
- Fragrance & Beauty like-for-like sales growth+9%
- Fine Fragrance like-for-like sales growth+15%
- Consumer Products like-for-like sales growth+9%
- Brand owners bringing more creation in-house
- Shift to lower-priced offerings and private label in some categories
- Faster reformulation cycles reducing switching friction
- SourceGivaudan Investor Presentation (July 2023)Jul 1, 2023
- NewsGivaudan 2026 half-year resultsJul 23, 2026
- Applies to
- Fragrance & Beauty
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 6, 2026
Patents, proprietary molecules and trade secrets protect exact formulas and processes. They support differentiation, but the public evidence does not show an essential ingredient that customers or competing fragrance houses cannot replace.
The group reported more than 5,000 active patents for 2024, but Fragrance Ingredients and Active Beauty sales fell 4.1% like-for-like in H1 2026; patent breadth alone does not establish indispensable ingredients.
- Fragrance & Beauty like-for-like sales growth+9%
- Fragrance Ingredients and Active Beauty like-for-like sales growth-3%
- Research and product development spendingCHF 286M+4%
- Active patents≥5,000
- Ingredient bans or restrictions forcing reformulation
- Patent expiry and competitive workarounds
- Disclosure risk through customer or supplier leakage
- SourceGivaudan investor presentation updated October 2025Oct 1, 2025
- SourceGivaudan Investor Presentation (July 2023)Jul 1, 2023
- Applies to
- Fragrance & Beauty
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 6, 2026
Large global innovation and creative platform (perfumers, science, digital tools) increases speed-to-brief and breadth of winning solutions, particularly in premium fine fragrance and active beauty.
Fine Fragrance grew 7.3% like-for-like in H1 2026 and research investment continued; creative scale supports new wins, while competitors retain similar capabilities.
- Fragrance & Beauty like-for-like sales growth+9%
- Fine Fragrance like-for-like sales growth+15%
- Fragrance Ingredients and Active Beauty like-for-like sales growth-3%
- Research and product development spendingCHF 286M+4%
- Active patents≥5,000
- Creation and application centres62
- Peer catch-up in AI-enabled creation and biotech
- R&D productivity declines (more spend, fewer wins)
- SourceGivaudan investor presentation updated October 2025Oct 1, 2025
- Source2025 Investor Presentation (updated October 2025)Oct 1, 2025
- SourceGivaudan Investor Presentation (July 2023)Jul 1, 2023
Profile change log
- Oct 6, 2026 · business change
A US court gave final approval to IFF’s end-user fragrance settlement. It leaves the claims against Givaudan and other defendants in place, so a competitor’s settlement does not end Givaudan’s civil exposure.
- Oct 6, 2026 · analyst revision
Taste & Wellbeing operating-excellence strength falls from 3 to 2 and its direction turns narrowing after the CSB findings. Fragrance IP is classified as proprietary-formula differentiation rather than an essential IP bottleneck. Each debate figure now links to a source that reports it.
- Oct 6, 2026 · business change
The US Chemical Safety Board found critical reactive-hazard and safeguard failures at Givaudan’s Louisville plant after the explosion that killed two workers. The site permanently closed, weakening the claim of superior operating reliability.
- Oct 6, 2026 · analyst revision
Supply-chain evidence supports operating reliability rather than exclusive control. The fragrance IP claim is weaker because patents and secret formulas do not establish an indispensable component. Revenue weights use FY2025 division sales rather than H1 2026. Both divisions now link to their shared markets, with trajectories and a testable investor debate.
- Oct 6, 2026 · business change
The CMA kept its fragrance investigation open with a December update planned; Givaudan continues to face legal uncertainty without an infringement finding.
- Oct 6, 2026 · business change
Givaudan reported CHF 83m of H1 legal settlements and provisions, reducing profit and showing that customer relationships do not protect against regulatory and product-liability exposure.
- Oct 6, 2026 · business change
Givaudan agreed to acquire a majority stake in Eurofragance, expanding regional fragrance creation and customer reach; terms are undisclosed and regulatory closing remains pending.
- Oct 6, 2026 · business change
Christian Stammkoetter became CEO after Gilles Andrier; his consumer-products experience adds customer insight while execution of the next growth cycle remains untested.
- Oct 6, 2026 · business change
Givaudan gained dual independent certification for its product carbon-footprint programme covering more than 90,000 products; standardised data helps customers meet procurement and reporting needs.
Industry & peers
Peer map
Peers appear on the map as their numbers are collected.
Global B2B fragrance and beauty ingredients
Fragrance compounds, proprietary scent molecules and active beauty ingredients sold to perfume, personal care and home care manufacturers. This is an ingredient and formulation market; retail perfume and cosmetics sales are excluded.
- Givaudan
- DSM-Firmenich
- IFF
- Symrise
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| GIVN | 87 | 43.7% | 16.9% | |
| Industry median | 11 | 75 | 43.7% | 14.8% |
| Sector median | 14 | 76 | 41.3% | 16.5% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Fine fragrance launches and growing interest in scent increase demand for new customer-specific creations.
- Personal care and home care consumption provides repeat volume alongside the more discretionary fine fragrance business.
- Online commerce and regional fragrance brands create new customer briefs and shorten product launch cycles.
- Natural and biotechnology ingredients create reformulation opportunities and can reduce dependence on scarce natural inputs.
- Consumer caution and customer destocking can reduce ingredient orders even when end-user consumption remains stable.
- Energy, feedstock and natural ingredient costs can rise before contract prices reset; tariffs add sourcing and logistics costs.
- A stronger reporting currency reduces translated sales and profit from global demand; company H1 2026 results show a material FX effect.
- Ingredient restrictions require reformulation, while competition investigations and civil litigation create legal and customer-trust risks.
- Higher interest rates raise the cost of carrying inventories and financing acquisitions for indebted suppliers; weaker consumer demand can extend the time between ingredient purchases and customer payment.
Bulls & bears
Can Givaudan turn its customer-specific creations and ingredient breadth into stronger growth and cash generation while absorbing legal costs, input inflation and the strong Swiss franc?
Arguments
What to watch
- 1Taste & Wellbeing like-for-like sales
- 2Fine Fragrance and Consumer Products like-for-like sales versus DSM-Firmenich and other peers
- 3Gross research spending and new-product evidence
- 4Operating cash flow and net working capital
- 5Separate legal charges, competition investigation outcomes and process-safety improvements
Next check: December 2026 CMA update and 27 January 2027 full-year results for cash conversion and North American Taste & Wellbeing demand.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 9, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 87/100 by <a href="https://www.findmymoat.com/stocks/XSWX:GIVN">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.